36氪精选：「智冉医疗」完成超3亿元A轮融资，加速侵入式脑机接口临床转化 | 早起看早期

Core Viewpoint - The article discusses the recent A-round financing of Zhiruan Medical, highlighting its focus on invasive brain-computer interface (BCI) technology and the advancements in flexible electrode development [7][9]. Company Overview - Zhiruan Medical has completed over 300 million yuan in A-round financing, with total funding since its establishment in 2022 nearing 500 million yuan [7][8]. - The company was co-founded by Dr. Fang Ying and Dr. Song Qi, both of whom have extensive backgrounds in neuroscience and AI medical technology [8]. Technology and Innovation - Zhiruan Medical specializes in invasive BCI technology, which allows for high-resolution neural signal collection and precise neuron modulation through implanted electrodes [9]. - The company has developed a high-throughput flexible electrode that has received patent authorization in both China and the U.S., achieving high efficiency in neuron signal collection [9][10]. - A fully implanted wireless signal acquisition system has been created, capable of collecting action potentials from up to 1024 channels, with a significant reduction in power consumption [10]. Research and Development - The company has established a high-precision brain data platform with over 20TB of animal neuron data and 6TB of human deep brain region data, enhancing model training speed and decoding performance [10]. - Zhiruan Medical has also developed a multi-degree-of-freedom implantation robot to improve the efficiency and safety of electrode implantation [10]. Industry Context - The global BCI industry is entering a rapid development phase, with companies like Neuralink making progress in human clinical trials [11]. - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and stability, which is essential for clinical applications [11]. - Invasive BCI technology holds potential for breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [11].